Last reviewed · How we verify

Amnion chorion membrane

Cairo University · FDA-approved active Biologic ✓ Verified May 2026 Quality 5/100

Amnion chorion membrane is a Biologic drug developed by Cairo University. It is currently FDA-approved. Also known as: bioresorbable membrane.

Amnion chorion membrane, also known as NeoThelium FT, is a treatment used to study the healing of chronic pressure ulcers, non-infected venous leg ulcers, and other conditions such as venous insufficiency and venous stasis. It is a vaccine component that works as an outer membrane vesicles vaccine antigen, derived from Neisseria meningitidis.

At a glance

Generic nameAmnion chorion membrane
Also known asbioresorbable membrane
SponsorCairo University
ModalityBiologic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Amnion chorion membrane

What is Amnion chorion membrane?

Amnion chorion membrane is a Biologic drug developed by Cairo University.

Who makes Amnion chorion membrane?

Amnion chorion membrane is developed and marketed by Cairo University (see full Cairo University pipeline at /company/cairo-university).

Is Amnion chorion membrane also known as anything else?

Amnion chorion membrane is also known as bioresorbable membrane.

What development phase is Amnion chorion membrane in?

Amnion chorion membrane is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing